X-linked/JJ
Gene/NN
Expression/NN
Profiles/NNS
by/IN
RNAi-Mediated/JJ
BRCA1/NN
Knockdown/NN
in/IN
MCF7/NN
Cells/NNS
./.
====================
Germ-line/NN
mutations/NNS
of/IN
the/DT
BRCA1/NN
gene/NN
confer/VBP
an/DT
increased/VBN
risk/NN
for/IN
breast/NN
and/CC
ovarian/JJ
cancers/NNS
./.
====================
BRCA1/NN
in/IN
female/JJ
cells/NNS
is/VBZ
directly/RB
related/JJ
with/IN
the/DT
maintenance/NN
of/IN
====================
the/DT
inactive/JJ
X/NN
chromosome/NN
(/(
Xi/NN
)/)
./.
====================
The/DT
effect/NN
by/IN
the/DT
loss/NN
of/IN
the/DT
BRCA1/NN
function/NN
on/IN
the/DT
X/NN
chromosome/NN
gene/NN
expression/NN
remains/VBZ
unclear/JJ
in/IN
cancer/NN
cells/NNS
./.
====================
We/PRP
attempted/VBD
to/TO
investigate/VB
the/DT
expression/NN
pattern/NN
of/IN
the/DT
X-linked/JJ
genes/NNS
by/IN
performing/VBG
BRCA1/NN
knockdown/VBN
via/IN
RNA/NN
interference/NN
in/IN
the/DT
MCF/NN
7/CD
breast/NN
cancer/NN
cell/NN
line/NN
./.
====================
The/DT
transcriptional/JJ
and/CC
translational/JJ
levels/NNS
of/IN
BRCA1/NN
were/VBD
decreased/VBN
over/IN
95/CD
%/NN
in/IN
the/DT
MCF/NN
7/CD
cells/NNS
after/IN
BRCA1/NN
knockdown/VBN
./.
====================
The/DT
expression/NN
patterns/NNS
of/IN
one/CD
hundred/VBN
ninety/CD
X-linked/JJ
genes/NNS
were/VBD
profiled/VBN
by/IN
the/DT
X/NN
chromosome-specific/JJ
cDNA/NN
arrays/NNS
./.
====================
A/DT
total/JJ
of/IN
seven/CD
percent/JJ
of/IN
the/DT
X-linked/JJ
genes/NNS
(/(
14/190/CD
)/)
were/VBD
aberrantly/RB
expressed/VBN
by/IN
over/IN
2-fold/JJ
in/IN
the/DT
MCF7-BRCA1/NN
knockdown/VBN
cells/NNS
,/,
which/WDT
contained/VBD
two/CD
up-regulated/VBN
genes/NNS
(/(
2/190/CD
,/,
1/CD
%/NN
)/)
and/CC
12/CD
down-/RB
regulated/VBN
genes/NNS
(/(
12/190/CD
,/,
6.3/CD
%/NN
)/)
./.
====================
It/PRP
is/VBZ
interesting/JJ
that/IN
72/CD
%/NN
of/IN
the/DT
aberrantly/RB
expressed/VBN
X-linked/JJ
genes/NNS
were/VBD
located/JJ
on/IN
the/DT
Xq/NN
(/(
10/14/CD
,/,
)/)
region/NN
./.
====================
Our/PRP$
data/NNS
suggests/VBZ
that/IN
BRCA1/NN
may/MD
not/RB
be/VB
important/JJ
to/TO
maintain/VB
X/NN
chromosome/NN
inactivation/NN
in/IN
cancer/NN
because/IN
the/DT
BRCA1/NN
knockdown/VBN
did/VBD
increase/VB
the/DT
expression/NN
of/IN
the/DT
only/RB
one/CD
percent/NN
of/IN
X-linked/JJ
genes/NNS
in/IN
the/DT
human/JJ
breast/NN
cancer/NN
cells/NNS
./.
====================
Breast/NN
cancer/NN
is/VBZ
a/DT
complex/NN
disease/NN
and/CC
a/DT
variety/NN
of/IN
risk/NN
====================
factors/NNS
are/VBP
involved/VBN
in/IN
conjunction/NN
with/IN
the/DT
observed/VBN
the/DT
BRCA1/NN
germline/NN
mutations/NNS
in/IN
familial/JJ
breast/NN
cancer/NN
./.
====================
Women/NNS
with/IN
a/DT
mutation/NN
in/IN
one/CD
allele/NN
of/IN
the/DT
BRCA1/NN
gene/NN
have/VBP
higher/JJR
rates/NNS
of/IN
breast/NN
,/,
ovarian/JJ
and/CC
other/JJ
cancers/NNS
(/(
Easton/JJ
eta/./FW
,/,
1993/CD
)/)
./.
====================
The/DT
hereditary/JJ
breast/NN
cancers/NNS
have/VBP
a/DT
different/JJ
gene/NN
expression/NN
pattern/NN
than/IN
do/VBP
the/DT
sporadic/JJ
cancers/NNS
(/(
Hedenfalk/NN
eta/./FW
,/,
2003/CD
)/)
./.
====================
BRCA1/NN
has/VBZ
multiple/JJ
functions/NNS
for/IN
DNA/NN
repair/NN
,/,
maintenance/NN
of/IN
genomic/JJ
integrity/NN
,/,
transcription/NN
regulation/NN
and/CC
cancer-/NN
suppression/NN
(/(
Venkitaraman/NNP
2002/CD
)/)
./.
====================
BRCA1/NN
mutation/NN
can/MD
regulate/VB
the/DT
expression/NN
of/IN
the/DT
various/JJ
genes/NNS
such/JJ
as/IN
oestrogen-receptor/NN
,/,
ERBB2/NN
,/,
p53/NN
and/CC
cyclin/NN
D1/NN
in/IN
familial/JJ
cancer/NN
(/(
Narod/NN
eta/./FW
,/,
2004/CD
)/)
./.
====================
However/RB
,/,
BRCA1/NN
mediated/VBN
transcriptional/JJ
regulation/NN
is/VBZ
not/RB
well/RB
understood/VBN
./.
====================
The/DT
overexpression/NN
of/IN
BRCA1/NN
induced/VBN
the/DT
genes/NNS
related/JJ
with/IN
the/DT
DNA/NN
damage-response/NN
,/,
the/DT
apoptotic/JJ
pathway/NN
,/,
the/DT
estrogen-response/NN
and/CC
the/DT
cytokine/NN
signal/NN
transduction/NN
pathway/NN
(/(
Welcsh/NNP
etal./FW
,/,
2002/CD
)/)
./.
====================
The/DT
expression/NN
pattern/NN
of/IN
the/DT
downstream/JJ
genes/NNS
according/VBG
to/TO
the/DT
loss/NN
of/IN
BRCA1/NN
is/VBZ
not/RB
clear/JJ
./.
====================
BRCA1/NN
may/MD
change/VB
the/DT
other/JJ
gene/NN
expressions/NNS
by/IN
direct/JJ
or/CC
indirect/JJ
protein/NN
interactions/NNS
with/IN
RNA/NN
polymerase/NN
II/CD
,/,
helicase/NN
A/NN
and/CC
etc/JJ
./.
====================
(/(
Rosen/NNP
eta/./FW
,/,
2003/CD
)/)
./.
====================
BRCA1/NN
in/IN
female/JJ
cells/NNS
is/VBZ
directly/RB
related/JJ
with/IN
the/DT
====================
maintenance/NN
of/IN
the/DT
inactive/JJ
X/NN
chromosome/NN
(/(
Xi/NN
)/)
(/(
Ganesan/NN
et/FW
a/./FW
,/,
2004/CD
)/)
./.
====================
BRCA1/NN
may/MD
be/VB
related/JJ
to/TO
the/DT
expression/NN
of/IN
the/DT
X/NN
chromosome/NN
genes/NNS
./.
====================
Xi-specific/JJ
transcript/NN
(/(
XIST/NN
)/)
is/VBZ
located/JJ
within/IN
the/DT
X-inactivation/NN
center/NN
(/(
XIC/NN
)/)
in/IN
the/DT
female/JJ
somatic/JJ
cells/NNS
,/,
and/CC
it/PRP
plays/VBZ
a/DT
crucial/JJ
role/NN
in/IN
Xi/JJ
./.
====================
Silencing/NN
of/IN
Xi/NN
is/VBZ
initiated/VBN
at/IN
one/CD
location/NN
on/IN
the/DT
XIC/NN
./.
====================
The/DT
coating/VBG
of/IN
XIST/NN
on/IN
Xi/NN
is/VBZ
supported/VBN
by/IN
BRCA1/NN
because/IN
BRCA1/NN
defect/NN
cancers/NNS
show/VBP
the/DT
Xi/NN
chromatin/NN
structural/JJ
defects/NNS
(/(
Ganesan/NN
eta/./FW
,/,
2002/CD
)/)
./.
====================
The/DT
role/NN
of/IN
BRCA1/NN
as/IN
related/JJ
with/IN
the/DT
XIST/NN
location/NN
in/IN
breast/NN
cancer/NN
suggests/VBZ
that/IN
the/DT
BRCA1/NN
is/VBZ
a/DT
key/JJ
point/NN
to/TO
maintain/VB
the/DT
Xi/NN
in/IN
breast/NN
cancer/NN
(/(
Sirchia/FW
eta/./FW
,/,
2005/CD
)/)
./.
====================
To/TO
study/VB
the/DT
differential/JJ
expression/NN
pattern/NN
of/IN
X-linked/JJ
genes/NNS
in/IN
BRCA1-associated/JJ
breast/NN
cancers/NNS
,/,
we/PRP
attempted/VBD
to/TO
investigate/VB
the/DT
change/NN
of/IN
expression/NN
of/IN
the/DT
190/CD
X-linked/JJ
genes/NNS
by/IN
inducing/VBG
BRCA1/NN
knockdown/VBN
in/IN
a/DT
human/JJ
breast/NN
cancer/NN
cell/NN
line/NN
having/VBG
the/DT
wild/JJ
type/NN
BRCA1/NN
,/,
MCF7/NN
by/IN
performing/VBG
an/DT
X/NN
chromosome/NN
specific/JJ
cDNA/NN
microarray/NN
./.
====================
Microarray/NN
technology/NN
has/VBZ
been/VBN
used/VBN
for/IN
the/DT
analysis/NN
of/IN
genome-wide/NN
gene/NN
expression/NN
profiles/NNS
,/,
and/CC
it/PRP
is/VBZ
a/DT
powerful/JJ
tool/NN
for/IN
analyzing/VBG
the/DT
variety/NN
genes/NNS
expression/NN
of/IN
samples/NNS
./.
====================
The/DT
mammalian/JJ
expression/NN
vector/NN
,/,
pSuper.retro.puro/NN
./.
====================
(/(
Oligoengine/NN
,/,
Seattle/JJ
,/,
WA/NN
)/)
was/VBD
used/VBN
for/IN
examining/VBG
the/DT
expression/NN
of/IN
RNAi/NN
in/IN
MCF7/NN
cells/NNS
./.
====================
The/DT
construct/NN
was/VBD
generated/VBN
by/IN
annealing/VBG
the/DT
following/VBG
complementary/JJ
oligonucleotides/NNS
./.
====================
The/DT
synthesized/VBN
oligonucleotides/NNS
were/VBD
forward/RB
,/,
5'-G/JJ
ATC/NN
CCC/NN
GAA/NN
AGT/NN
ACG/NN
AGA/NN
TTT/NN
AGTCTT/NN
CAA/NN
GAG/NN
AGACTA/NN
AAT/NN
CTC/NN
GTACTTTCT/NN
I/NN
I/NN
I/NN
TGG/NN
AAA-3/NN
'/``
,/,
and/CC
reverse/JJ
,/,
5/CD
’/NN
-AG/NN
CTT/NN
TTC/NN
CAA/NN
AAA/NN
GAA/NN
AGT/NN
ACG/NN
AGA/NN
TTT/NN
AGT/NN
CTC/NN
TCT/NN
TG/NN
A/DT
AGA/NN
CTA/NN
AAT/NN
CTC/NN
GTA/NN
CTT/NN
TCG/NN
GG-3/NN
’/NNP
,/,
and/CC
they/PRP
were/VBD
inserted/VBN
into/IN
the/DT
pSUPER/NN
vector/NN
at/IN
the/DT
Bgl/JJ
n/NN
and/CC
HindlU/JJ
sites/NNS
(/(
Fabbro/NNP
etal./FW
,/,
2004/CD
)/)
====================
Human/JJ
breast/NN
cancer/NN
MCF7/NN
cells/NNS
were/VBD
obtained/VBN
from/IN
American/NN
Type/NN
Culture/NN
Collection/NN
(/(
Rockville/NN
,/,
MD/NN
)/)
./.
====================
Cells/NNS
were/VBD
grown/VBN
in/IN
RPMI-1640/NN
medium/NN
(/(
Gibco/NN
BRL/NN
,/,
Cergy/NN
Pontoise/JJ
,/,
France/NN
)/)
,/,
and/CC
this/DT
was/VBD
supplemented/VBN
with/IN
10/CD
%/NN
fetal/JJ
bovine/NN
serum/NN
,/,
1/CD
%/NN
penicillin/NN
and/CC
1/CD
%/NN
streptomycin/NN
./.
====================
The/DT
cells/NNS
were/VBD
seeded/VBN
onto/IN
60/CD
cm/NN
2/CD
dishes/NNS
and/CC
then/RB
transfected/VBN
at/IN
70-80/CD
%/NN
confluence/NN
with/IN
8/CD
ug/NN
of/IN
plasmid/NN
DNA/NN
by/IN
using/VBG
Lipofectamin/NN
2000/CD
reagent/JJ
according/VBG
to/TO
the/DT
manufacture/NN
’/CD
s/NNS
instructions/NNS
(/(
Invitrogen/NN
,/,
Carlsbad/NN
,/,
====================
CA/NN
,/,
U.S.A/NN
)/)
./.
====================
The/DT
cells/NNS
were/VBD
analyzed/VBN
at/IN
72/CD
h/NN
post­/JJ
transfection/NN
with/IN
performing/JJ
puromycin/NN
selection/NN
./.
====================
The/DT
total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
the/DT
cultured/VBN
cells/NNS
with/IN
====================
using/VBG
QIAGEN/NN
RNA-Mini/NNS
kits/NNS
according/VBG
to/TO
the/DT
manufacture/NN
’/CD
s/NNS
instructions/NNS
(/(
Qiagen/NN
,/,
Valencia/NN
,/,
CA/NN
)/)
./.
====================
All/DT
the/DT
RNA/NN
preparations/NNS
were/VBD
treated/VBN
with/IN
DNase/NN
I/CD
(/(
Roche/NNP
,/,
Boehringer-Mannhein/NN
,/,
Germany/NNP
)/)
./.
====================
For/IN
the/DT
RNA/NN
analysis/NN
,/,
equivalent/JJ
amounts/NNS
of/IN
total/JJ
RNA/NN
served/VBD
as/IN
the/DT
template/NN
for/IN
cDNA/NN
synthesis/NN
with/IN
using/VBG
reverse-transcriptase/NN
(/(
Invitrogen/NN
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
U.S.A/NN
)/)
./.
====================
Real-time/NN
RT-PCR/NN
assays/NNS
were/VBD
carried/VBN
out/RP
in/IN
a/DT
fluorometric/JJ
thermal/JJ
cycler/NN
(/(
Rotor-Gene/NN
2000/CD
,/,
Corbett/NN
Research/NN
,/,
Australia/NN
)/)
./.
====================
For/IN
performing/VBG
the/DT
quantitative/JJ
real-time/NN
RT-PCR/NN
,/,
SYBR-Green/NNP
(/(
Qiagen/NN
,/,
Valencia/NN
,/,
CA/NNP
)/)
was/VBD
added/VBN
to/TO
the/DT
reaction/NN
mixture/NN
,/,
and/CC
the/DT
fluorescence/NN
was/VBD
measured/VBN
after/IN
each/DT
cycle/NN
./.
====================
After/IN
the/DT
native/JJ
cDNA/NN
copy/NN
number/NN
of/IN
each/DT
gene/NN
was/VBD
calculated/VBN
with/IN
using/VBG
the/DT
comparative/JJ
AACT/NN
method/NN
for/IN
each/DT
sample/NN
,/,
the/DT
relative/JJ
ratios/NNS
of/IN
the/DT
tested/VBN
gene/NN
for/IN
GAPDH/NN
were/VBD
generated/VBN
./.
====================
The/DT
date/NN
is/VBZ
shown/VBN
as/IN
the/DT
mean/JJ
and/CC
standard/JJ
deviation/NN
values/NNS
of/IN
the/DT
three/CD
measurements/NNS
per/FW
data/NNS
point/VBP
./.
====================
Whole-cell/RB
extracts/NNS
were/VBD
prepared/VBN
from/IN
the/DT
cell/NN
lysates/NNS
in/IN
a/DT
buffer/NN
that/IN
contained/VBD
50/CD
mM/NN
Tris-HCI/NN
pH/NN
8.0/CD
,/,
150/CD
mM/NN
NaCI/NN
,/,
1/CD
%/NN
NP-40/CD
,/,
1/CD
mM/NN
PMSF/NN
,/,
5/CD
mM/NN
EDTA/NN
and/CC
4/CD
mg/ml/NN
of/IN
protease/NN
inhibitors/NNS
cocktail/NN
(/(
Sigma/NN
,/,
MO/NN
,/,
USA/NNP
)/)
./.
====================
The/DT
samples/NNS
were/VBD
separated/VBN
on/IN
8/CD
%/NN
SDS/NN
polyacrylamide/NN
gels/NNS
and/CC
then/RB
blotted/VBD
onto/IN
PVDF/NN
membranes/NNS
./.
====================
The/DT
primary/JJ
antibodies/NNS
used/VBN
were/VBD
anti-BRCA1/JJ
(/(
C-20/NN
,/,
Santa/NN
Cruz/NN
Biotechnology/NN
,/,
1:200/CD
)/)
and/CC
anti-//JJ
?/.
-actin/NN
(/(
AC-15/NN
,/,
Sigma/NN
,/,
1:5,000/CD
)/)
./.
====================
After/IN
incubation/NN
with/IN
horseradish/JJ
peroxidase-coupled/VBD
secondary/JJ
antibodies/NNS
(/(
anti-rabbit/JJ
,/,
Upstate/JJ
,/,
1:1000/CD
or/CC
anti-mouse/JJ
,/,
Calbiochem/NNP
,/,
1:1000/CD
)/)
,/,
the/DT
signals/NNS
were/VBD
detected/VBN
by/IN
performing/VBG
chemiluminescence/NN
with/IN
using/VBG
ECL/NN
(/(
Amersharm/NN
,/,
Pharmacia/NN
,/,
Piscataway/NN
,/,
NJ/NNP
)/)
./.
====================
One-hundred/VBN
ninety/CD
X-linked/JJ
clones/NNS
were/VBD
provided/VBN
by/IN
KRIBB/NN
(/(
Korea/NN
Research/NN
Institute/JJ
Bioscience/NN
and/CC
Biotechnology/NN
)/)
,/,
and/CC
the/DT
clone/NN
information/NN
is/VBZ
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
Those/DT
clones/NNS
were/VBD
spotted/VBN
in/IN
a/DT
X-linked/JJ
cDNA/NN
microarray/NN
from/IN
Digital/JJ
Genomics/NNS
(/(
Digital/JJ
Genomics/NNS
,/,
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
The/DT
RNA/NN
was/VBD
prepared/VBN
by/IN
using/VBG
RiboAmp/NN
RNA/NN
amplification/NN
kits/NNS
according/VBG
to/TO
the/DT
manufacture/NN
’/CD
s/NNS
instruction/NN
(/(
Arcturus/NN
,/,
Carlsbad/NN
,/,
CA/NNP
)/)
./.
====================
Each/DT
3/CD
pg/NN
of/IN
aRNA/JJ
(/(
antisense/JJ
RNA/NN
)/)
was/VBD
labeled/VBN
with/IN
either/CC
Cy3-UTP/NN
or/CC
Cy5-UTP/NN
(/(
NEN/NN
Life/NN
Science/NNP
Products/NNS
,/,
Boston/NNP
,/,
MA/NN
,/,
U.S.A./NNP
)/)
during/IN
the/DT
reverse/JJ
transcription/NN
(/(
RT/NN
)/)
(/(
Invitrogen/NN
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
U.S.A/NNP
)/)
./.
====================
After/IN
hybridization/NN
,/,
the/DT
slide/JJ
was/VBD
dried/VBN
by/IN
centrifugation/NN
,/,
and/CC
then/RB
it/PRP
was/VBD
scanned/VBN
on/IN
a/DT
ScanArray/NN
4000XL/JJ
(/(
Packard/NN
Bioscience/NN
,/,
Billerica/NNP
,/,
MA/NN
,/,
U.S.A./NNP
)/)
./.
====================
The/DT
unified/JJ
image/NN
was/VBD
quantified/VBN
with/IN
using/VBG
ImaGene™/JJ
version/NN
4.0/CD
(/(
BioDiscovery/NNP
,/,
Inc./NNP
,/,
Los/NN
Angeles/NNS
,/,
CA/NN
,/,
U.S.A./NNP
)/)
./.
====================
Data/NNS
analysis/NN
were/VBD
performed/VBN
using/VBG
the/DT
GeneSight™/NN
3.10/CD
(/(
BioDiscovery/NNP
,/,
Inc./NNP
,/,
Los/NN
Angeles/NNS
,/,
CA/NN
,/,
U.S.A./NNP
)/)
./.
====================
We/PRP
used/VBD
RNAi/NN
for/IN
examining/VBG
the/DT
gene/NN
expression/NN
change/NN
according/VBG
to/TO
BRCA1/NN
knockdown/VBN
in/IN
the/DT
MCF7/NN
cells/NNS
./.
====================
The/DT
RNAi/NN
was/VBD
produced/VBN
by/IN
employing/VBG
the/DT
pSuper.retro.puro-vector/NN
system/NN
,/,
which/WDT
was/VBD
indicated/VBN
in/IN
the/DT
material/JJ
and/CC
methods/NNS
section/NN
(/(
Fabbro/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Successful/JJ
use/NN
of/IN
this/DT
technology/NN
depends/VBZ
on/IN
effective/JJ
mRNA/NN
degradation/NN
and/CC
the/DT
protein/NN
turnover/NN
./.
====================
Bae/NN
et/FW
al/JJ
reported/VBD
the/DT
knockdown/JJ
of/IN
BRCA1/NN
by/IN
using/VBG
the/DT
RNAi/NN
method/NN
in/IN
MCF7/NN
cells/NNS
(/(
Bae/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
We/PRP
used/VBD
the/DT
====================
same/JJ
vector/NN
with/IN
identical/JJ
sequences/NNS
for/IN
the/DT
BRCA1/NN
knockdown/VBN
./.
====================
We/PRP
assessed/VBD
the/DT
silencing/NN
effect/NN
BRCA1-RNAi/NN
on/IN
its/PRP$
target/NN
mRNA/NN
by/IN
RT-PGR/NN
and/CC
Western/NN
blotting/NN
./.
====================
Real-time/NN
RT-PCR/NN
data/NNS
(/(
Fig/NN
./.
====================
1a/NN
./.
)/)
====================
showed/VBD
that/IN
BRCA1/NN
mRNA/NN
level/NN
was/VBD
markedly/RB
downregulated/VBD
in/IN
MCF7/NN
cells/NNS
====================
transfected/VBN
with/IN
BRCA1-RNAi/NN
for/IN
72/CD
h./FW
The/DT
Y/NN
axis/NN
indicates/VBZ
the/DT
expression/NN
level/NN
of/IN
BRCA1/NN
mRNA/NN
that/WDT
was/VBD
normalized/VBN
by/IN
using/VBG
GAPDH/JJ
./.
====================
The/DT
data/NNS
are/VBP
presented/VBN
as/IN
the/DT
mean/NN
±SE/NN
of/IN
the/DT
individual/JJ
values/NNS
from/IN
three/CD
separate/JJ
experiments/NNS
./.
====================
The/DT
knockdown/JJ
level/NN
of/IN
the/DT
BRCA1/NN
protein/NN
was/VBD
also/RB
confirmed/VBD
by/IN
western/NN
blot/NN
analysis/NN
(/(
Fig/NN
./.
====================
1b/NN
)/)
./.
====================
BRCA1/NN
protein/NN
was/VBD
not/RB
detected/VBN
at/IN
====================
72/CD
hrs/NNS
after/IN
transfection/NN
./.
====================
The/DT
97/CD
%/NN
BRCA1/NN
knockdown/VBN
was/VBD
shown/VBN
at/IN
both/CC
the/DT
transcriptional/JJ
and/CC
translational/JJ
levels/NNS
./.
====================
X-linked/JJ
gene/NN
expression/NN
patterns/NNS
by/IN
cDNA/NN
====================
microarray/NN
====================
We/PRP
performed/VBD
the/DT
cDNA/NN
microarray/NN
to/TO
identify/VB
the/DT
expression/NN
pattern/NN
of/IN
the/DT
X-linked/JJ
genes/NNS
according/VBG
to/TO
BRCA1/NN
knockdown/VBN
./.
====================
Our/PRP$
X-linked/JJ
cDNA/NN
microarray/NN
contained/VBD
190/CD
X-linked/JJ
genes/NNS
;/:
the/DT
lists/NNS
of/IN
genes/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
total/JJ
RNA/NN
was/VBD
extracted/VBN
from/IN
both/CC
BRCA1-RNAi/NN
and/CC
mock-transfected/JJ
MCF7/NN
cells/NNS
./.
====================
The/DT
probe/NN
was/VBD
generated/VBN
via/IN
RT-PCR/NN
from/IN
the/DT
BRCA1/NN
-RNAi/NN
samples/NNS
and/CC
the/DT
mock-transfected/JJ
samples/NNS
,/,
respectively/RB
./.
====================
We/PRP
first/RB
compared/VBN
the/DT
X-linked/JJ
gene/NN
expression/NN
by/IN
performing/VBG
BRCA1/NN
knockdown/VBN
./.
====================
To/TO
verify/VB
the/DT
different/JJ
incorporation/NN
rates/NNS
of/IN
the/DT
Cy-3/NN
and/CC
Cy-5/NN
dye/NN
,/,
we/PRP
swapped/VBD
the/DT
fluorescent/JJ
dye/NN
(/(
Fig/NN
./.
====================
2a/CD
)/)
./.
====================
The/DT
schematic/JJ
diagram/NN
for/IN
the/DT
change/NN
of/IN
the/DT
expression/NN
levels/NNS
of/IN
the/DT
X-linked/JJ
genes/NNS
was/VBD
according/VBG
to/TO
the/DT
X/NN
chromosomal/JJ
====================
physical/JJ
map/NN
(/(
Fig/NN
./.
====================
2b/NN
)/)
./.
====================
The/DT
overall/JJ
differentially/RB
expressed/VBN
genes/NNS
between/IN
the/DT
BRCA1/NN
-RNAi/NN
and/CC
the/DT
mock-transfected/JJ
MCF7/NN
cells/NNS
were/VBD
described/VBN
according/VBG
to/TO
the/DT
X/NN
chromosome/NN
loci/NNS
(/(
Fig/NN
./.
====================
2b/NN
)/)
./.
====================
The/DT
Y/NN
axis/NN
represents/VBZ
the/DT
expression/NN
level/NN
====================
(/(
log/NN
2/CD
ratio/NN
>/JJR
1/CD
,/,
log/NN
2/CD
ratio/NN
>/JJR
-1/CD
)/)
in/IN
the/DT
BRCA1-RNAi/NN
transfected/VBN
====================
MCF7/NN
cells/NNS
./.
====================
Similar/JJ
results/NNS
were/VBD
shown/VBN
by/IN
the/DT
three/CD
repeated/VBN
experiments/NNS
./.
====================
A/DT
total/JJ
of/IN
seven/CD
percent/JJ
of/IN
the/DT
190/CD
X-linked/JJ
genes/NNS
(/(
14/190/CD
)/)
were/VBD
differentially/RB
expressed/VBN
,/,
and/CC
28/CD
%/NN
were/VBD
at/IN
Xp/NN
and/CC
72/CD
%/NN
were/VBD
at/IN
Xq/NN
./.
====================
Two/CD
genes/NNS
(/(
2/190,1/CD
%/NN
)/)
,/,
RBMIOand/CC
VBP1/NN
,/,
were/VBD
up-regulated/VBN
,/,
and/CC
12/CD
genes/NNS
(/(
12/190/CD
,/,
6.3/CD
%/NN
)/)
,/,
UBE1/NN
,/,
OFD1/NN
,/,
GYG2/NN
,/,
NONO/NN
,/,
TAF9L/NN
,/,
TSPAN6/NN
,/,
MCTS1/NN
,/,
MTMR1/NN
,/,
FAM3A/NN
,/,
GDI1/NN
,/,
CXorf40/NN
and/CC
SLC10A4/NN
,/,
were/VBD
down-regulated/VBN
by/IN
over/IN
2-fold/JJ
in/IN
the/DT
BRCA1-RNAi/NN
transfected/VBN
MCF7/NN
cells/NNS
./.
====================
The/DT
genotypes/NNS
of/IN
hereditary/JJ
breast/NN
cancers/NNS
are/VBP
reflected/VBN
in/IN
the/DT
different/JJ
gene/NN
expression/NN
profiles/NNS
(/(
Rosen/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
However/RB
,/,
the/DT
expression/NN
pattern/NN
of/IN
the/DT
X-linked/JJ
====================
genes/NNS
is/VBZ
incompletely/RB
understood/VBN
in/IN
BRCA1-related/JJ
breast/NN
cancer/NN
./.
====================
This/DT
study/NN
is/VBZ
the/DT
first/JJ
data/NNS
concerning/VBG
the/DT
expression/NN
pattern/NN
of/IN
the/DT
X-linked/JJ
genes/NNS
after/IN
BRCA1/NN
knockdown/VBN
with/IN
using/VBG
RNAi/JJ
by/IN
performing/VBG
DNA/NN
microarray/NN
experiments/NNS
./.
====================
After/IN
the/DT
BRCA1/NN
knockdown/VBN
,/,
we/PRP
experimented/VBD
with/IN
the/DT
cDNA/NN
microarray/NN
to/TO
identify/VB
the/DT
expression/NN
pattern/NN
of/IN
the/DT
X-linked/JJ
genes/NNS
./.
====================
A/DT
new/JJ
function/NN
for/IN
BRCA1/NN
was/VBD
reported/VBN
in/IN
the/DT
heterochromatin/NN
formation/NN
,/,
especially/RB
in/IN
the/DT
inactive/JJ
X/NN
chromosome/NN
(/(
Ganesan/NN
etal./FW
,/,
2002/CD
)/)
./.
====================
However/RB
,/,
it/PRP
remains/VBZ
unclear/JJ
whether/IN
BRCA1/NN
modulates/VBZ
the/DT
expression/NN
of/IN
the/DT
X-linked/JJ
genes/NNS
to/TO
a/DT
global/JJ
(/(
affecting/VBG
the/DT
entire/JJ
X/NN
chromosome/NN
)/)
or/CC
specific/JJ
degree/NN
./.
====================
Welcsh/JJ
et/FW
al/JJ
./.
====================
have/VBP
reported/VBN
the/DT
upregulation/NN
of/IN
the/DT
XIST/NN
RNA/NN
levels/NNS
,/,
and/CC
this/DT
was/VBD
followed/VBN
by/IN
the/DT
BRCA1/NN
expression/NN
(/(
Welcsh/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
However/RB
,/,
we/PRP
found/VBD
that/IN
the/DT
XIST/NN
expression/NN
was/VBD
not/RB
changed/VBN
by/IN
BRCA1/NN
knockdown/VBN
(/(
data/NNS
not/RB
shown/VBN
)/)
,/,
even/RB
though/IN
the/DT
XIST/NN
expression/NN
was/VBD
low/JJ
in/IN
the/DT
MCF7cells/NNS
./.
====================
Sudbral/JJ
etal/JJ
./.
====================
employed/VBN
Xchromosome-specific/JJ
cDNA/NN
arrays/NNS
to/TO
identify/VB
the/DT
genes/NNS
that/WDT
escaped/VBD
from/IN
the/DT
X-inactivation/NN
(/(
Sudbrak/NN
etal./FW
,/,
2001/CD
)/)
./.
====================
We/PRP
also/RB
employed/VBN
X/NN
chromosome-specific/JJ
cDNA/NN
arrays/NNS
that/DT
spotted/VBN
190/CD
X/NN
chromosome/NN
genes/NNS
to/TO
identify/VB
the/DT
differentially/RB
expressed/VBN
X-linked/JJ
genes/NNS
according/VBG
to/TO
the/DT
BRCA1/NN
knockdown/VBN
(/(
Jeong/JJ
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
However/RB
,/,
almost/RB
all/DT
the/DT
X-linked/JJ
genes/NNS
were/VBD
not/RB
changed/VBN
by/IN
BRCA1/NN
knockdown/VBN
in/IN
the/DT
MCF7/NN
cells/NNS
./.
====================
Our/PRP$
data/NNS
is/VBZ
the/DT
first/JJ
to/TO
report/VB
the/DT
X-linked/JJ
gene/NN
expression/NN
according/VBG
to/TO
BRCA1/NN
knockdown/VBN
./.
====================
We/PRP
suggest/VBP
that/IN
BRCA1/NN
may/MD
not/RB
involve/VB
the/DT
X-linked/JJ
gene/NN
expression/NN
,/,
at/IN
least/JJS
the/DT
MCF7/NN
cancer/NN
cells/NNS
./.
====================
We/PRP
supposed/VBD
that/IN
both/CC
the/DT
X/NN
chromosomes/NNS
of/IN
the/DT
MCF7/NN
human/JJ
breast/NN
carcinoma/NN
cell/NN
line/NN
may/MD
have/VB
active/JJ
(/(
Sirchia/NN
etal./FW
,/,
2005/CD
)/)
./.
====================
Further/RB
investigations/NNS
are/VBP
needed/VBN
to/TO
determine/VB
whether/IN
BRCA1/NN
is/VBZ
related/JJ
to/TO
Xi/JJ
through/IN
such/JJ
epigenetic/JJ
mechanisms/NNS
as/IN
chromatin/NN
modification/NN
./.
====================
